RT Journal Article SR Electronic(1) A1 Ibuki, Kentaro A1 Funahashi, Shin-Ichi A1 Yamamoto, Hiroshi A1 Nakamura, Masami A1 Igarashi, Tatsuhiko A1 Miura, Tomoyuki A1 Ido, Eiji A1 Hayami, Masanori A1 Shida, HisatoshiYR 1997 T1 Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. JF Journal of General Virology, VO 78 IS 1 SP 147 OP 152 DO https://doi.org/10.1099/0022-1317-78-1-147 PB Microbiology Society, SN 1465-2099, AB To develop effective vaccines against infection with human T cell leukaemia virus type I (HTLV-I), we constructed a recombinant vaccinia virus (WR- SFB5env) synthesizing the HTLV-I envelope (Env) gp46 protein under the control of a strong promoter, termed the ATI hybrid promoter. WR- SFB5env expressed a large quantity of gp46. In cynomolgus monkeys (Macaca fascicularis) immunized with WR-SFB5env, anti-HTLV-I Env antibody, including neutralizing antibody, was induced and remained at a high level until 136 weeks (2 6 years) post-infection (p.i.). These immunized monkeys had HTLV-I Env-specific cytotoxic T lymphocyte activity. At 136 weeks p.i., the immunized monkeys were challenged with an HTLV-I-produc- ing cynomolgus T lymphocyte cell line. Neither HTLV-I antigen nor HTLV-I proviruses were detected in peripheral blood mononuclear cells, lymph nodes or spleens of the WR-SFB5env- immunized monkeys, in contrast to non-immunized control monkeys. These results indicate that a single immunization with WR-SFB5env induced prolonged humoral and cellular immune responses to HTLV-I and protected the monkeys against virus challenge., UL https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-78-1-147